217 related articles for article (PubMed ID: 32527287)
21. Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells.
Soung YH; Pruitt K; Chung J
Sci Rep; 2014 Jan; 4():3846. PubMed ID: 24457910
[TBL] [Abstract][Full Text] [Related]
22. Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers.
Lawson CD; Fan C; Mitin N; Baker NM; George SD; Graham DM; Perou CM; Burridge K; Der CJ; Rossman KL
Cancer Res; 2016 Jul; 76(13):3826-37. PubMed ID: 27216196
[TBL] [Abstract][Full Text] [Related]
23. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Wen YH; Ho A; Patil S; Akram M; Catalano J; Eaton A; Norton L; Benezra R; Brogi E
Breast Cancer Res Treat; 2012 Aug; 135(1):93-102. PubMed ID: 22538771
[TBL] [Abstract][Full Text] [Related]
24. ID4 regulates mammary gland development by suppressing p38MAPK activity.
Dong J; Huang S; Caikovski M; Ji S; McGrath A; Custorio MG; Creighton CJ; Maliakkal P; Bogoslovskaia E; Du Z; Zhang X; Lewis MT; Sablitzky F; Brisken C; Li Y
Development; 2011 Dec; 138(23):5247-56. PubMed ID: 22069192
[TBL] [Abstract][Full Text] [Related]
25. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
26. Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth.
Korang-Yeboah M; Patel D; Morton D; Sharma P; Gorantla Y; Joshi J; Nagappan P; Pallaniappan R; Chaudhary J
Oncotarget; 2016 Oct; 7(42):68072-68085. PubMed ID: 27487149
[TBL] [Abstract][Full Text] [Related]
27. Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers.
Zvelebil M; Oliemuller E; Gao Q; Wansbury O; Mackay A; Kendrick H; Smalley MJ; Reis-Filho JS; Howard BA
Breast Cancer Res; 2013 Mar; 15(2):R25. PubMed ID: 23506684
[TBL] [Abstract][Full Text] [Related]
28. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.
Chen SS; Claus R; Lucas DM; Yu L; Qian J; Ruppert AS; West DA; Williams KE; Johnson AJ; Sablitzky F; Plass C; Byrd JC
Blood; 2011 Jan; 117(3):862-71. PubMed ID: 21098398
[TBL] [Abstract][Full Text] [Related]
29. Paracrine Signaling from Breast Cancer Cells Causes Activation of ID4 Expression in Tumor-Associated Macrophages.
Donzelli S; Sacconi A; Turco C; Gallo E; Milano E; Iosue I; Blandino G; Fazi F; Fontemaggi G
Cells; 2020 Feb; 9(2):. PubMed ID: 32054109
[TBL] [Abstract][Full Text] [Related]
30. AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A hypusination-TCF4 axis.
Liao R; Chen X; Cao Q; Bai L; Ma C; Dai Z; Dong C
Breast Cancer Res; 2024 Apr; 26(1):70. PubMed ID: 38654332
[TBL] [Abstract][Full Text] [Related]
31. The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1.
Pruszko M; Milano E; Forcato M; Donzelli S; Ganci F; Di Agostino S; De Panfilis S; Fazi F; Bates DO; Bicciato S; Zylicz M; Zylicz A; Blandino G; Fontemaggi G
EMBO Rep; 2017 Aug; 18(8):1331-1351. PubMed ID: 28652379
[TBL] [Abstract][Full Text] [Related]
32. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
[TBL] [Abstract][Full Text] [Related]
34. AGR2 and AGR3 play an important role in the clinical characterization and prognosis of basal like breast cancer.
de Moraes CL; Cruz E Melo N; Valoyes MAV; Naves do Amaral W
Clin Breast Cancer; 2022 Feb; 22(2):e242-e252. PubMed ID: 34462207
[TBL] [Abstract][Full Text] [Related]
35. [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].
Noetzel E; Veeck J; Horn F; Hartmann A; Knüchel R; Dahl E
Pathologe; 2008 Nov; 29 Suppl 2():319-27. PubMed ID: 18807039
[TBL] [Abstract][Full Text] [Related]
36. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer.
Ray PS; Wang J; Qu Y; Sim MS; Shamonki J; Bagaria SP; Ye X; Liu B; Elashoff D; Hoon DS; Walter MA; Martens JW; Richardson AL; Giuliano AE; Cui X
Cancer Res; 2010 May; 70(10):3870-6. PubMed ID: 20406990
[TBL] [Abstract][Full Text] [Related]
37. ID4 predicts poor prognosis and promotes BDNF-mediated oncogenesis of colorectal cancer.
Ha CT; Cheng CY; Zheng MY; Hsu TH; Miao CC; Lee CJ; Wang HD; Pan ST; Chou YT
Carcinogenesis; 2021 Jul; 42(7):951-960. PubMed ID: 33993270
[TBL] [Abstract][Full Text] [Related]
38. Id4 dependent acetylation restores mutant-p53 transcriptional activity.
Knowell AE; Patel D; Morton DJ; Sharma P; Glymph S; Chaudhary J
Mol Cancer; 2013 Dec; 12():161. PubMed ID: 24330748
[TBL] [Abstract][Full Text] [Related]
39. Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth.
Pathania R; Ramachandran S; Mariappan G; Thakur P; Shi H; Choi JH; Manicassamy S; Kolhe R; Prasad PD; Sharma S; Lokeshwar BL; Ganapathy V; Thangaraju M
Cancer Res; 2016 Jun; 76(11):3224-35. PubMed ID: 27197203
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.
Joshi JB; Patel D; Morton DJ; Sharma P; Zou J; Hewa Bostanthirige D; Gorantla Y; Nagappan P; Komaragiri SK; Sivils JC; Xie H; Palaniappan R; Wang G; Cox MB; Chaudhary J
Mol Oncol; 2017 Apr; 11(4):337-357. PubMed ID: 28252832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
